Your browser doesn't support javascript.
loading
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj, Mitja; Eikema, Diderik-Jan; Koster, Linda; Platzbecker, Uwe; Sockel, Katja; Finke, Jürgen; Kröger, Nicolaus; Forcade, Edouard; Nagler, Arnon; Eder, Matthias; Tischer, Johanna; Broers, Annoek E C; Kuball, Jürgen; Wilson, Keith M O; Hunault-Berger, Mathilde; Collin, Matthew; Russo, Domenico; Corral, Lucía López; Helbig, Grzegorz; Mussetti, Alberto; Scheid, Christof; Gurnari, Carmelo; Raj, Kavita; Drozd-Sokolowska, Joanna; Yakoub-Agha, Ibrahim; Robin, Marie; McLornan, Donal P.
Afiliação
  • Nabergoj M; Hematology Service, Institut Central des Hôpitaux (ICH), Hôpital du Valais, Sion, Switzerland. mitja.nabergoj@hopitalvs.ch.
  • Eikema DJ; EBMT Statistical Unit, Leiden, The Netherlands.
  • Koster L; EBMT Leiden Study Unit, Leiden, The Netherlands.
  • Platzbecker U; Medical Clinic and Policinic 1, Leipzig, Germany.
  • Sockel K; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Finke J; University of Freiburg, Freiburg, Germany.
  • Kröger N; Department for Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany.
  • Forcade E; CHU Bordeaux, Pessac, France.
  • Nagler A; Chaim Sheba Medical Center, Tel-Hashomer, Israel.
  • Eder M; Hannover Medical School, Hannover, Germany.
  • Tischer J; Klinikum Grosshadern, Munich, Germany.
  • Broers AEC; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Kuball J; University Medical Centre, Utrecht, The Netherlands.
  • Wilson KMO; University Hospital of Wales, Cardiff, UK.
  • Hunault-Berger M; CHRU, Angers, France.
  • Collin M; Adult HSCT unit, Newcastle, UK.
  • Russo D; Unit of Bone Marrow Transplantation, University of Brescia, ASST Spedali Civili, Brescia, Italy.
  • Corral LL; Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Helbig G; Silesian Medical Academy, Katowice, Poland.
  • Mussetti A; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain.
  • Scheid C; University of Cologne, Cologne, Germany.
  • Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133, Rome, Italy.
  • Raj K; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
  • Drozd-Sokolowska J; Department of Haematology, University College London Hospitals NHS Trust, London, UK.
  • Yakoub-Agha I; University Clinical Centre, Medical University of Warsaw, Warsaw, Poland.
  • Robin M; CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France.
  • McLornan DP; Hopital Saint- Louis, APHP, Université de Paris Cité, Paris, France.
Bone Marrow Transplant ; 59(3): 395-402, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38195984
ABSTRACT
Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006-2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Segunda Neoplasia Primária / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Linfoma Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans / Middle aged Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Segunda Neoplasia Primária / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Linfoma Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans / Middle aged Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça